United States Infectious Disease Biomarker Testing Market to Witness Rapid Growth in Coming Years
Growing prevalence of
infectious diseases including COVID-19 to foster the growth of United States
infectious disease biomarker testing market
According to
TechSci Research report, “United States Infectious Disease
Biomarker Testing Market By Product (Assays, Platforms), By Application
(Respiratory Infection, Sexually Transmitted Infection, Bloodstream and
Hospital-Acquired Infection, Urinary Tract Infection, Gastro-Intestinal
Infection, Central Nervous System Infection, Others), By Technology (PCR, NGS,
ELISA or EIA, IHC, ISH, Others), By Pathogen (Virus (Influenza, HIV-AIDS,
Hepatitis, HPV, Others), Bacteria (Tuberculosis, CT/NG, Hospital-Acquired
Infection, Others), By End User (Hospitals and Clinics, Diagnostic Centers,
Research Laboratories, Others), By Region, Forecast & Opportunities, 2025”, the market is anticipated to witness robust growth during
the forecast period on account of rising prevalence of infectious diseases such
as COVID-19, which has led to extensive
research activities for its diagnostic and cure. Moreover, increasing funding
by government for infectious disease diagnostics and presence of advanced
healthcare system in the country are acting as key growth drivers for United
States infectious disease biomarker testing market. In addition to this, growth
in the biomarker identification market is also supporting the growth of
infectious disease biomarker testing. With advancements in molecular techniques,
the market is expected to register significant growth through 2025.
Additionally, advancements in biomarker testing platforms,
coupled with frequent outbreak of
various infectious diseases around the world is creating high demand for
infectious disease biomarker testing. The increasing demand for novel molecular
diagnostics testing tools due to increasing cases of coronavirus in United
States is further augmenting the demand for infectious disease biomarker
testing products. Furthermore, biomarker
testing offers disease surveillance and confirmation of cases during an
outbreak and hence, is gaining traction in United States.
Browse XX market data Tables and XX Figures spread through XXX Pages and an in-depth TOC on "United States Infectious Disease
Biomarker Testing Market"
https://www.techsciresearch.com/report/united-states-infectious-disease-biomarker-testing-market/5120.html
United States infectious
disease biomarker testing market is segmented based on product, application,
technology, pathogen, end user and region. Based on product, the market can be
segmented into assays and platforms. Among the two, assays are gaining traction
in United States infectious disease biomarker testing market and are expected
to register high growth during the forecast period. Assays come with one-time
use and hence require repetitive purchase. Also, the large availability of a wide
range of assays being offered by leading companies is fueling their demand in
United States.
Based on
technology, the United States infectious disease biomarker testing market can
be categorized into PCR, NGS, ELISA or EIA, IHC, ISH and others. Among these, PCR
dominated the market in 2019 owing to high prominence PCR based products and
high adoption rates compared to other technologies. However, NGS technology is
expected to register fastest CAGR during the forecast period as they have
faster turnaround time for high sample volumes.
Major players operating in the United
States infectious disease biomarker testing market include Abbott Laboratories,
Inc., Agilent Technologies, Inc., Becton, Dickinson and Company, Bio-Rad
Laboratories, Inc., Danaher Corporation, Hologic, Inc., PerkinElmer, Inc.,
Thermo Fisher Scientific, Inc., Hoffmann-La Roche Inc., Quest Diagnostics
Incorporated and Qiagen Sciences, Inc. The companies are undertaking growth
strategies such as partnerships and alliances to strengthen their business
position in United States.
Download
Sample Report @
https://www.techsciresearch.com/sample-report.aspx?cid=5120
Customers can
also request for 10% free customization on this report.
“The presence of
leading market players and increasing funding for biomarker testing is making
United States a prominent market for infectious disease biomarker testing. Moreover, the
country has highly developed healthcare system, which is supporting the growth
of infectious disease biomarker testing market. As the country is witnessing
increasing cases of coronavirus, the market is expected to grow significantly
during the forecast period,” said Mr. Karan Chechi, Research Director with
TechSci Research, a research based global management consulting firm.
“United States Infectious Disease Biomarker
Testing Market By Product (Assays, Platforms), By Application (Respiratory
Infection, Sexually Transmitted Infection, Bloodstream and Hospital-Acquired
Infection, Urinary Tract Infection, Gastro-Intestinal Infection, Central
Nervous System Infection, Others), By Technology (PCR, NGS, ELISA or EIA, IHC,
ISH, Others), By Pathogen (Virus (Influenza, HIV-AIDS, Hepatitis, HPV, Others),
Bacteria (Tuberculosis, CT/NG, Hospital-Acquired Infection, Others), By End
User (Hospitals and Clinics, Diagnostic Centers, Research Laboratories, Others),
By Region, Forecast & Opportunities, 2025” has evaluated the future growth potential of United States infectious
disease biomarker testing market and provides statistics & information on
market size, structure and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges and opportunities in United States infectious
disease biomarker testing market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]